Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Energy agency chief warns of 'black April' for oil supplies - 2'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
- 3Figure out How to Score Huge with Open Record Rewards
- 4How to watch 'A Charlie Brown Christmas' for free this weekend
- 5NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Why most Jewish Israelis back the death penalty for terrorists
- She was moments away from giving birth. The hospital discharged her
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- Step by step instructions to Protect Your Speculations with Cd Rates
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
